Abstract
Sézary syndrome is a primary cutaneous T-cell lymphoma (CTCL) with severe clinical manifestations characterized by erythroderma, lymph node and blood involvement. In our retrospective database-based study we reviewed data of 23 patients (8 women and 15 men) diagnosed and treated with Sézary syndrome at our Indtitute from 1st January 2016 to 30th June 2022. The median follow-up time of patients was 42 (6-167) months. According to the course of the disease, 17.4% of patients went into complete remission, 30.4% achieved partial remission, 13% remained stable, while progression was seen in 39.1% of the cases. The most frequently used therapeutic entities were extracorporeal photopheresis (95.6%), bexarotene (52.2%), methotrexate (43.5%) and acitretine (34.8%). The diagnosis and treatment of Sézary syndrome remains a significant challenge. In all cases of erythroderma, histological sampling is recommended, and if CTCL is confirmed, staging examinations for TNMB classification should be performed. In the early stages of the disease, access to skin-directed therapies (phototherapy, radiotherapy) and immunomodulatory systemic treatments (ECP, retinoids, MTX) is crucial, while cooperation with hematological and stem cell transplantation centers is essential in the care of patients showing progression.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
